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SUMMARY
Gap junctions, as low-resistance pathways for intercellular communication, have been 
suggested to play a role in acute ischaemia-induced arrhythmias and also in the 
antiarrhythmic effect of ischaemic preconditioning. However, the mechanism of their 
contribution has not been clarified.
Therefore, we aimed (1) to examine gap junction function, changes in impulse conduction and 
the severity of arrhythmias during a 60 min occlusion of the LAD; (2) to evaluate the effects 
of gap junction coupler/uncoupler drugs (rotigaptide and carbenoxolone) applied before and 
continuously during ischaemia; (3) to assess the effect of preconditioning on ischaemia- 
induced uncoupling, conduction impairments and arrhythmias, and (4) to study the possible 
trigger role of gap junctions in ischaemic preconditioning with the use of gap junction 
modifier drugs. The severity of arrhythmias and changes in impulse conduction were 
investigated in anaesthetised, open-chest dogs whereas gap junction function was studied both 
in vivo and in vitro.
We have confirmed the role of gap junctional uncoupling in the lb phase of acute ischaemia- 
induced arrhythmias but also pointed out that closure of gap junctions can lead to arrhythmias 
only during a certain period of ischaemia. The use of gap junction modifier drugs 
corroborated that the timing of gap junctional uncoupling is crucial in arrhythmogenesis.
We have shown that improvement in impulse conduction due to reduced gap junctional 
uncoupling contributes to the antiarrhythmic effect of preconditioning.
We have also found that whereas the gap junction opener rotigaptide did not influence, the 
gap junction uncoupler carbenoxolone attenuated the protective effect of preconditioning 
when it was applied during the preconditioning ischaemia. This emphasizes the role of gap 
junctions in the transfer of those endogenous mediators, which are released by the 
preconditioning stimulus and induce the protective effect. The fact that carbenoxolone, 
applied by itself before the sustained ischaemia, resulted in a protective effect similar to 
preconditioning, raised the supposition that gap junctional uncoupling or some other function 
of connexin proteins may also serve as a trigger for preconditioning.
These experiments show that modification of gap junctions either prior to or during ischaemia 
significantly influence the severity of ischaemia-induced arrhythmias.
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1. INTRODUCTION
Sudden cardiac death, resulting from malignant ventricular arrhythmias of acute myocardial 
ischaemia, is one of the major causes of death in the developed countries. Unfortunately, 
currently available antiarrhythmic drugs, which usually target cardiac ion channels and 
pumps, are not adequately safe since they may also induce severe arrhythmias, especially 
under ischaemic conditions. Therefore, interventions either targeting structures other than 
sarcolemmal ion channels, such as gap junctions, or utilizing endogenous adaptive 
mechanisms of the heart such as ischaemic preconditioning, could be the bases of new 
therapeutic strategies to prevent and/or attenuate acute ischaemia-induced ventricular
arrhythmias.
1.1 Time course and mechanisms of acute ischaemia-induced arrhythmias
Acute myocardial ischaemia, resulting from severe stenosis or complete occlusion of a 
coronary artery, is usually accompanied by such metabolic and electrophysiological 
alterations in the affected tissue that lead to severe, often lethal ventricular arrhythmias. In 
large animals, and probably also in humans, these arrhythmias are most severe during the first 
30 min of ischaemia and occur in two distinct phases [1]. The la phase of these arrhythmias 
appears between 3 and 8 min of ischaemia; this is followed by a short arrhythmia-free period 
and, around 15 min of ischaemia, by a new arrhythmia phase. This lb phase of arrhythmias, 
during which the risk of ventricular fibrillation is the highest, lasts up to 30 min of ischaemia. 
Thereafter, ectopic activity diminishes and remains low; there are no or only a few and less 
malignant arrhythmias in the subacute phase (24-72 hours ol ischaemia).
There are different mechanisms underlying the two phases of early arrhythmias. Already 
within the first minutes of ischaemia, the lack of glucose and oxygen supply results in 
intracellular acidosis and a reduction of high-energy phosphate deposits [2, 3], Since the 
energy produced by intact cellular metabolism is essential for the proper function of 
membrane ion transporters, this ischaemia-induced energy deficit rapidly leads to severe ionic 
imbalance, including the loss of K+ and an increase in intracellular Na+ and Ca2+ [4], The 
subsequent depolarization, further enhanced by the accumulation of lysophosphoglycerides 
[5], partially inactivates the Na+ channels and produces those conduction abnormalities, which 
are responsible for the phase la of ischaemia-induced arrhythmias [6].
The causes of the short arrhythmia-free period between phase la and lb are less known but it 
is usually explained by the enhancement of membrane pump function as catecholamines are 
released from sympathetic nerve endings [7, 8]. However, this mechanism can counteract the 
ischaemic damage only for several minutes and totally depletes the intracellular energy 
sources.
During the lb phase, both the loss of ATP and further accumulation of catecholamines end in 
intracellular Ca2+ overload [7], which may enhance triggered activity [9, 10]. Catecholamines 
are arrhythmogenic also by increasing the spatial heterogeneity of the effective refractory 
period throughout the border of the ischaemic and the normally perfused myocardium [11]. 
The closure of gap junctions, channels specialized for direct intercellular communication, is 
also suggested to be an important determinant of phase 1 b arrhythmias.
1.2 Structure, function and pharmacology of myocardial gap junctions
Gap junctions are low-resistance pathways for direct intercellular communication, allowing 
the exchange of molecules smaller than 1 kDa with minor selectivity for charge or molecule 
weight. These structures, together with other cell adhesion proteins, are packed into gap 
junction plaques, which are located predominantly at the end-to-end connections of 
neighbouring cells. To form a direct cytoplasmic connection, each cell provides a 
hemichannel, a hexamer of connexin protein subunits.
Connexins are membrane proteins with four transmembrane domains and intracellular N- and 
C-terminals. Based on their molecule weight, more than 20 connexin isoforms have been 
identified [12], three of which are abundant in the heart muscle. Connexin 40 and 45 occur 
predominantly in the atria and in the conduction system, whereas connexin 43 (Cx43) is the 
main gap junction forming protein in the working myocardium of the ventricles [13].
These isoforms differ mainly in the length of their C terminal, a domain that contains several 
Ser and Tyr amino acid residues as targets of phosphorylation/dephosphorylation by several 
kinases and phosphatases of the cellular signal transduction cascades [14, 15, 16]. 
Phosphorylation/dephosphorylation regulates both membrane delivery, internalization, 
degradation, opening/closure and conductance of gap junctions [16]. On the intracellular loop, 
there is a pH sensor sequence as well; this domain is responsible for the closure of gap 
junctions at low pH [17]. Furthermore, many other factors, which indicate the metabolic state 
of the cell and are altered by ischaemia (intracellular Ca , ATP and lipid metabolites), are 
able to regulate the function of these intercellular connective structures [18, 19, 20].
Besides cellular signalling and metabolism, there are many agents that can be used as 
pharmacological modifiers of gap junction function. Volatile anaesthetics, some long-chain 
fatty acids and polyalcohols such as palmitoleic acid and heptanol, dicoumarol, glycyrrhetinic 
acid and its derivatives, as well as peptides mimicking the extracellular domains of connexins 
are all known to uncouple gap junctions [21]. The gap junction specificity of these substances, 
however, largely differs. For example, heptanol may affect other ion channels especially in 
doses higher than 0.5 mM [22], whereas the glycyrrhetinic acid derivative carbenoxolone is 
reported to be rather selective for gap junctions [23, 24].
There are pharmacological means to keep gap junctions open as well, even in the presence of 
triggers for gap junction closure. In 1980, an antiarrhythmic peptide with gap junction coupler 
properties was found in bovine atria [25]. Synthetic analogues of this peptide are also shown 
to maintain gap junctional communication under such circumstances which otherwise favour 
uncoupling [26]. Rotigaptide (formerly known as ZP123), due to its increased protease 
resistivity afforded by the D-amino acids contained in the molecule, is known to be the most 
stable synthetic antiarrhythmic peptide [27].
The importance of the cellular regulation and/or pharmacological modulation of gap junction 
function lies not only in the direct metabolic connection they provide, but also in their role in 
cardiac impulse propagation, therefore impairments of gap junction function may lead to
severe arrhythmias.
1.3 Role o f gap junctions in acute ischaemia-induced arrhythmias
During the course of acute myocardial ischaemia, the loss of ATP, intracellular acidosis, as 
well as accumulation of lipid metabolites and intracellular Ca2+ trigger gap junctional 
uncoupling. This is clearly exemplified by that the increase in intracellular Ca2+ coincide with 
a steep increase in tissue resistivity, a parameter indicating gap junctional uncoupling in the 
ischaemic rabbit papillary muscle [28], In the same model, Kléber et al. [29] used the cable 
theory to separate extra- and intracellular components of tissue resistivity and provided 
further evidence that increase in intracellular resistivity, a more proper indicator of gap 
junctional uncoupling, starts at around 15 min of ischaemia. Furthermore, it has also been 
demonstrated in anaesthetised pigs that gap junctional uncoupling, determined by a steep rise 
in tissue impedance, coincided with the appearance of lb arrhythmias [30].
The role of gap junctions in arrhythmogenesis can also be studied by pharmacological 
modulation of gap junctional coupling. In myocyte strands in vitro [31], as well as in isolated
rabbit hearts [32], uncoupling of gap junctions by palmitoleic acid results in a markedly 
slower and meandering impulse conduction. Slowing of impulse conduction in the presence 
of the relatively selective gap junction uncoupler, carbenoxolone, has also been demonstrated 
in both isolated rabbit hearts [23] and human hearts in vivo [33], Conduction slowing 
mediated by gap junctional uncoupling may favour the formation of reentry by decreasing its 
wavelength (the product of conduction velocity and the effective refractory period). Indeed, in 
genetically engineered mice in which the expression of connexin 43 was substantially 
reduced, an increased propensity for arrhythmias could be observed [34], especially if the loss 
of Cx43 expression was heterogenous throughout the heart [35, 36] or if those mice were 
subjected to myocardial ischaemia [37]. There is also evidence that reentrant arrhythmias 
triggered after 3 hours of ischaemia [38], or formed spontaneously during reperfusion [39], as 
well as ouabain-, hypokalaemia-, acidosis- or ischaemia-induced conduction slowing were 
effectively attenuated by the gap junction coupler rotigaptide [27,40,41].
It must be noted that on one hand, closure of gap junctions by isolating dying, unexcitable 
myocytes from their surviving, excitable neighbours may limit both infarct size [42, 43] and 
the spread of triggered activity [10, 44]. On the other hand, however, it may end in severe, 
even life-threatening ventricular arrhythmias, which provide a reason for the research of drugs 
or other treatments to reduce these arrhythmias.
1.4 The antiarrhythmic effect of ischaemic preconditioning and possible role 
of gap junctions in the protection
In 1986, Murry and his co-workers reported that short, sublethal cycles of myocardial 
ischaemia/reperfusion, prevent both the loss of ATP and cell death during a subsequent, more 
prolonged ischaemic insult [45]. This phenomenon has been termed as ischaemic 
preconditioning. It has also been shown that preconditioning not only reduces 
ischaemia/reperfusion induced cell death (infarct size) [45, 46], but improves cardiac function 
[47], and markedly reduces ventricular arrhythmias [48] both during ischaemia and 
reperfusion. This protection lasts for only 1 or 2 hours after the preconditioning stimulus 
(early phase or first window of protection), but reappears 16-24 hours later and lasts for 48-72 
hours (late phase or second window of protection) [49, 50, 51]. The present study, however, 
focused only on the early phase of preconditioning-induced protection.
During the preconditioning stimulus, many endogenous substances (such as adenosine, 
bradykinin, reactive oxygen species, nitric oxide [51, 52, 53]) have been proved to be released
and, by the activation of cellular signalling cascades, induce protection (triggers). Although 
the precise mechanisms by which preconditioning exerts its protective effect are not fully 
understood, the proposed end-effectors include sarcolemmal ion channels/transporters, 
antiapoptotic- and mitochondrial proteins [51, 53, 54].
Gap junctions, as key factors in cardiac impulse propagation and arrhythmogenesis, are also 
suggested to participate in preconditioning. However, there is only one study, which 
examined directly the role of gup junctions in the antiarrhythmic effect of ischaemic 
preconditioning: Cinca et al. [55] have shown that in the in vivo pig heart, both the occurrence 
of phase lb arrhythmias and gap junctional uncoupling (determined as a steep rise in tissue 
resistivity) were delayed by preconditioning. Although Shome et al [56] have also suggested 
that gap junctional uncoupling is reduced by preconditioning in anaesthetised dogs, they 
concluded to the extent of gap junctional uncoupling only from the decrease in ST-segment 
elevation due to increased intercellular resistance and from changes in conduction velocity, 
instead of any, more direct measurement.
The concept that several endogenous substances are released during the trigger phase of 
preconditioning leads to the supposition that gap junctions, by facilitating the propagation of 
at least some of these substances, may play a role already in the induction of the protective 
effect. Indeed, Li et al. [57] have found that heptanol, administered in a dose of 0.5 mM 
before the preconditioning stimulus, abrogated the infarct size-reducing effect of 
preconditioning. Similarly, in isolated rabbit hearts, IP3-induced cytoprotection was 
completely abolished if gap junctions were simultaneously uncoupled by heptanol or by the 
peptide Gap27 [58]. Unfortunately, in these studies only infarct size was determined as an 
endpoint of the protective effect and, as to our present knowledge, there is no study on the 
trigger role of gap junctions in the antiarrhythmic effect of preconditioning.
Aims o f the study
On the basis of our presently incomplete knowledge about the role of gap junctions in acute 
ischaemia-induced arrhythmias, and of the potential benefits of gap junction modification, 
either by drugs or by ischaemic preconditioning as tools to reduce these arrhythmias, this 
study aimed:
(1) To assess the role of gap junctions in ischaemia-induced arrhythmias in anaesthetised, 
open-chest dogs by comparing arrhythmia severity and changes in impulse conduction 
with gap junction function;
(2) To examine the effect of gap junction coupler/uncoupler drugs, given prior to and 
during ischaemia on these parameters, thus to further investigate the importance of 
gap junction function in arrhythmogenesis,
(3) To study the effects of ischaemic preconditioning on ischaemia-induced gap junctional 
uncoupling, conduction abnormalities and ventricular arrhythmias in this model;
(4) To reveal how gap junctions, if they do, contribute to the trigger phase of ischaemic 
preconditioning.
2. MATERIALS AND METHODS
2.1 Experimental animals
Adult mongrel dogs of either sex weighing between 8.5 and 46 kg (mean 21 ± 7 kg) were 
used in these studies. The origin and upkeep of the dogs were in accordance with Hungarian 
law (XXVIII, chapter IV, paragraph 31) regarding large experimental animals which
conforms to EU laws.
2.2 Surgical preparation
Anaesthesia was induced by pentobarbital (30 mg/kg, i.v.) and maintained with a mixture of 
chloralose and urethane (60 and 200 mg/kg, respectively) administered into the femoral vein. 
Catheters were inserted into the right femoral artery and, via the left carotid artety, into the 
cavity of the left ventricle to measure arterial blood pressure and left ventricular pressure 
changes. From left ventricular pressure changes, positive and negative dP/dtm„  values were 
calculated to evaluate ventricular contraction and relaxation. All these parameters were 
measured with a Plugsys Haemodynamic Apparatus (Hugo Sachs Electronics, Germany) and 
registered on a Graphtec Thermal Array Recorder.
Dogs were intubated and ventilated with room air with a Harvard respirator (Harvard 
Apparatus, Natick, MA, USA) at a rate and volume sufficient to maintain arterial blood gases 
and pH within physiological limits. The chest and the pericardium were opened and the left 
anterior descending coronary artery (LAD), proximal to its first diagonal branch, was 
prepared for occlusion. Distal to the occlusion site, a cannula was introduced into a small side 
branch of the LAD for drug administration. After surgery, the chest was covered to avoid 
cooling and drying. Body temperature was regularly monitored and kept at 37 ± 0.5 °C by
means of a heating pad.
2.3 Evaluation o f ventricular arrhythmias
Ventricular arrhythmias were evaluated from a lead II ECG according to the Lambeth 
conventions [59], modified as follows: the numbers of ventricular premature beats (VPBs) 
and tachycardiac episodes (VT, defined as four of more consecutive VPBs) as well as the 
incidence of ventricular fibrillation (VF%) were assessed.
2.4 Electrophysiological techniques to assess conduction and action potential 
properties
In some of the experiments, a composite electrode was sutured onto the ventricular surface 
expected to be ischaemic upon LAD occlusion. The composite electrode gives a summerized 
recording of bipolar electrograms measured from 24 epicardial points, resulting in a single 
large spike in case of normal activation, whereas it is prolonged and fractionated if the 
activation is slow and/or inhomogeneous. This signal was measured by a custom-made 
amplifier unit and recorded on a Graphtec Thermal Array Recorder; the inhomogeneity of 
electrical activation was expressed as the duration of the signal in ms.
In the rest of the experiments, instead of the composite electrode, an activation mapping 
electrode containing 31 unipolar leads was sutured above the ischaemic area. The 31 unipolar 
ECGs, together with the lead II ECG, were recorded on a computer and analysed off-line. 
Activation maps, showing local activation times in ms for each electrode point, were created 
from representative normal beats in every 2 min of the experiments. Local activation times 
were defined as the dV/dtmjn of the QRS complex; the beginning of the QRS on the lead II 
ECG was considered as time zero. From activation maps, the total activation time (TAT) was 
determined as the time difference between the first and the last activation and normalized for 
the average cycle length of 400 ms (TATn4oo). In order to exclude the potential effect of 
rotigaptide on action potential upstroke velocity, dV/dtmjn values of the unipolar recordings 
(reflecting the dV/dtmax of the local action potential) were measured from five randomly 
selected electrode points at baseline and after 10 min of rotigaptide (1 pg/kg/min) infusion. 
On the same manner, activation-recovery intervals (ARI), which are proportional to action 
potential duration, were also determined as the difference between the local activation and 
local repolarization times (the latter assessed as the dV/dtmax of the T wave) and normalized to 
the average cycle length of 400 ms.
2.5 Measurement o f myocardial electrical impedance
Tissue impedance was measured with a four-pinned electrode (for detailed description of the 
electrode, see [60]) inserted into the center of the potentially ischaemic myocardium and fixed 
to the epicardium with sutures. The whole electrode was electrically insulated except for the 
tip of the electrode pins, which were in contact with the midmyocardium. Through the outer 
pair of electrode pins, a 10 pA alternating current with a frequency of 8 kHz was applied.
Voltage was measured between the inner pair of electrodes with a custom-made signal 
processing unit connected to a lock-in amplifier (SR830 DSP; Stanford Research Systems, 
California, USA). According to the concept of impedance measurement, gap junctional 
uncoupling increases the capacity of the cell membranes, thus increases resistivity and shifts 
the voltage curve to the right compared to the current. This phase delay can be expressed in 
degrees, the more negative the phase angle value, the more pronounced is the phase delay 
induced by gap junctional uncoupling. Raw data, together with tissue resistivity (in Ohnvcm) 
and phase angle values (in °) gained in every 4 sec, were stored on a computer. During off­
line analysis, relative changes in resistivity and phase angle were plotted at 1 min intervals. 
To attenuate small oscillations due to ventilation movements, the mean of five consecutive 4- 
sec measurements was used for each minute.
2.6 Myocardial tissue sampling at the end of the occlusion
At the end of the occlusion period, hearts were arrested by an intravenous bolus of saturated 
KC1, excised rapidly and washed in ice-cold saline.
For the measurement of gap junctional metabolic coupling, solutions containing both Lucifer 
Yellow (Sigma, 1.5 mg/ml) and TRITC-dextrane (Sigma, 3.5 mg/ml) were prepared 
previously with Tyrode solution and stored at -20 °C until use. Freshly excised transmural 
tissue blocks originating from both the ischaemic region and a further, non-ischaemic region 
of the left ventricle were submerged into the dye mix for 15 min at 20 °C; the solution 
containing the normoxic sample was oxygenated during the staining period. After staining, 
samples were fixed in 4% paraformaldehyde and stored at 4 °C.
For the purpose of western blot analysis, transmural tissue samples from both the ischaemic 
and a further, non-ischaemic area of the left ventricle, were excised and snap-frozen in liquid 
nitrogen, then stored at -80 °C until use.
2.7 Assessment of gap junctional metabolic coupling
Samples stained and fixed previously, were dehydrated (30% sucrose, for at least 1 day) and 
25 pm sections from the midmyocardial layer were made at -20 °C in a cryostat (Leica). 10 
image pairs per sample were taken with a fluorescent microscope (Olympus IX 70) coupled to 
a CCD-camera and the penetration of the two dyes was quantified with the ImageJ software 
by expressing the areas stained by Lucifer Yellow (LY) and TRITC-dextrane (TD) in square
pixels. Since the penetration of the small-molecule weight Lucifer Yellow depends on the 
open/closed state of gap junctions, whereas large molecules of TRITC-dextrane label only 
cells injured during sample excision, gap junctional metabolic coupling can be determined as 
the ratio of LY/TD areas. Gap junction permeability measured in the ischaemic samples was 
expressed as a percentage of the permeability measured in the non-ischaemic self-controls.
2.8 Western blot analysis o f the phosphorylational status o f connexin 43
Frozen tissue samples were grinded in liquid nitrogen with a mortar and pestle, then 180-200 
mgs of the powdered tissue were further homogenized in ice-cold lysis buffer (250 mM 
sucrose, 20 mM Tris-HCl, 10 mM -mercaptoethanol, 10 mM sodium orthovanadate, 0.5 % 
protease inhibitor cocktail (Sigma), at pH 7.4). Tissue homogenates were centrifuged at 2000 
g for 15 min at 4 °C, supernatants were collected and the homogenization step, together with 
the centrifugation was repeated with the pellets. The collected supernatants (total protein 
extracts lacking nuclear and contractile elements as well as un-homogenized connective 
tissue) were ultracentrifuged at 100 000 g for 45 min at 4 °C, and the pellets (the membrane 
fraction) were dissolved in lysis buffer and stored at -80 °C. The protein content of these 
membrane isolates were determined according to the method of Lowry and 20 pg protein of 
each sample was separated on 12% polyacrylamide gels. Proteins were then transferred to 
PVDF membranes (Millipore). Unspecific binding capacity of the membrane was blocked by 
incubation in 5% milk for 1 hour, then blots were labeled overnight with the primary antibody 
(Rabbit polyclonal anti-Cx43 (Zymed), dilution 1:2000). After subsequent incubation with the 
secondary antibody (HRP-conjugated goat anti-rabbit IgG (Santa Cruz), dilution 1:8000) for 1 
hour, blots were developed with the ECL Plus kit (Amersham) and scanned with a Typhoon 
laser scanner. The densities of the phosphorylated (43-46 kDa) and dephosphorylated Cx43 
bands (40-43 kDa) were quantified with the ImageQuant software and their amounts were 
expressed as a percentage of the total membrane Cx43 content.
Although the effect of Cx43 phosphorylation, as mentioned under point 1.2, depends largely 
on the kinase and the site of phosphorylation [16], this method still can be used for the 
determination of gap junctional coupling since it is commonly accepted that highly 
phosphorylated Cx43 forms are related to the open state of gap junctions, while 
dephosphorylation is associated with gap junction closure.
2.9 Statistical analysis
All data are expressed as mean ± SEM. The total number of VPBs and VT episodes were 
analysed with the Kruskal-Wallis test and the incidence of VF was analysed with the Fisher 
exact test. Impedance changes were compared to the control group in each 5 min of the 
ischaemia with Student’s t-test. Changes in TAT^oo were also compared to changes in the 
control group with Student’s t-test, in every 2 min between 2-8 and 14-30 min of ischaemia 
and in every 6 min between 30 and 60 min of ischaemia. Gap junction permeability and 
connexin 43 phosphorylation results were analysed with one-way ANOVA using Fisher’s 
LSD post hoc test. Changes were considered significant at p < 0.05.
2.10 Drugs
Stock solutions of carbenoxolone (Sigma) and rotigaptide (formerly known as ZP123, 
synthetized at the Department of Medical Chemistry, University of Szeged, Hungary) were 
made with saline (carbenoxolone: 500 pM, stored at 4 °C no longer than 1 week; rotigaptide: 
2 mg/ml, stored at -20 °C until use). Stocks were diluted with saline to the final concentration 
of the infusion just before use.
2.11 Experimental protocols
2.11.1 Protocols to study the effects of gap junction coupler/uncoupler agents 
administered before and during myocardial ischaemia
These are illustrated on Figure 1. Dogs were randomly selected into five groups. Control dogs 
(n=6) were subjected to a 60 min occlusion of the LAD; intracoronary infusion of saline was 
started 10 or 15 min before and maintained throughout the occlusion period. In the CBX 
group (n=8), 50 pM carbenoxolone was administered in intracoronary infusion 15 min prior 
to and during the LAD occlusion. The timing of the infusion was selected using literature 
data; it has been reported earlier that in the isolated rabbit heart, carbenoxolone exerted its 
maximal effect on conduction velocity after 15 min of continuous administration [23], In 
other three groups of dogs, rotigaptide (RG) infusion in a dose of 0.04 pg/kg/min (n=7), 0.2 
Pg/kg/min (n=8) or 1 pg/kg/min (n=7), was started 10 min prior to and maintained over the
whole occlusion period.
2.11.2 Protocols to study the role of gap junctions in the antiarrhythmic effect of 
ischaemic preconditioning
As illustrated on Figure 2, dogs were randomly selected into six groups. Control dogs (n=6) 
were infused with saline on the intracoronary route for 20 min, and subjected to a 60 min 
LAD occlusion 20 min later. In the preconditioned group (PC; n=8), in the presence of the 
same saline infusion, a 5 min preconditioning ischaemia/reperfusion was performed 20 min
prior to the prolonged ischaemia. To study the possible trigger role of gap junctions in PC, 
carbenoxolone was administered in an intracoronary infusion 20 min prior to the LAD 
occlusion, in the presence (CBX+PC, n=l 1) or absence (CBX bef.; n=15) of preconditioning. 
In two other groups, rotigaptide was infused via the coronary side branch 20 min prior to the 
prolonged occlusion, either by itself (RG bef.; n=8) or in combination with PC (RG+PC; 
n=8).
Figure 2. Protocols to study the role o f gap junctions in the antiarrhythmic effect o f  
ischaemic preconditioning.
2.11.3. Data handling in the control groups
Since the time of saline administration (prior to and during LAD occlusion or prior to only) 
did not cause any significant difference in any of the measured parameters between the two 
control groups, their data were pooled and handled as one group with a case number of 12.
3. RESULTS
3.1. Effects o f gap junction coupler/uncoupler agents on acute ischaemia- 
induced haemodynamic and electrophysiological alterations
3.1.1 Haemodynamic changes following saline, carbenoxolone, and rotigaptide infusion
These are shown in Table 1. The 20 min administration of carbenoxolone/rotigaptide, similar 
to the 20 min infusion of saline, resulted in no significant change in any of the measured 
haemodynamic parameters.
3.1.2 Haemodynamic changes during LAD occlusion
Table 2 shows maximal changes in the measured haemodynamic parameters during the LAD 
occlusion in control as well as in carbenoxolone- and rotigaptide-treated dogs. Coronary 
occlusion resulted in a significant decrease in arterial blood pressure and left ventricular 
pressure. The dP/dtmax values were also significantly reduced, whereas left ventricular end- 
diastolic pressure was elevated following occlusion. All these changes were similar to the 
controls in the CBX- and rotigaptide-treated dogs. Heart rate did not show any significant 
change in any of the groups.
3.1.3 Verification of the gap junction specific effect of rotigaptide
dV/dtmin values of local electrograms and activation-recovery intervals (ARI) corrected to 
cycle length, measured during the 10 min administration of rotigaptide (1 pg/kg/min) in five 
dogs, are listed in Table 3. The lack of any significant change verifies that neither the 
upstroke velocity, nor the duration of local action potentials was affected by this 
concentration of the peptide. In whole-cell patch clamp studies performed on isolated canine 
myocytes, the peptide proved to be ineffective on sarcolemmal Ica,L> Ito, I«r and I«i currents as 
Well (data not shown).
Table 1. Haemodynamic changes following intracoronary saline/carbenoxolone/rotigaptide administration (mean ± SEM).
S a lin e C B X
R o t ig a p t id e  ( p g /k g /m in )
0 .0 4  0 .2  1
p r e p o s t p r e p o s t p r e p o s t p r e p o s t p r e p o s t
SA B P (H gm m ) 147±3 145±3 145±8 147±7 149±5 145±6 145±8 146±8 146±12 142±11
D A B P (H gm m ) 102±2 102±2 98±6 101±5 101±3 99±3 96±6 98±6 107±8 102±8
M A B P  (H gm m ) 117±2 117±2 115±6 118±6 117±4 114±4 112±7 114±7 120±9 115±9
L V SP (H gm m ) 148±3 146±3 141±7 142±7 147±67 143±67 144±8 144±8 145±11 139±9
L V E D P  (H gm m ) 6.4±0.3 6.5±0.2 6.2±0.7 7±0.6 6.7±0.4 6.9±0.3 6.1±0.3 6.4±0.4 6.6±0.7 6.4±0.4
+ d P /d t (H gm m /s) 3337±67 3295±78 3 0 9 8 Ü 3 9 3 2 1 U 1 8 7 3 3 9 5 Ü 0 9 3 2 8 1 Ü 3 5 3196±162 3 1 17±155 3336±329 3267±403
-d P /d t (H gm m /s) 2 9 0 U 1 9 2890±70 2812±173 2700±164 2 769± 119 2712±108 2948±199 2 9 6 2 Ü 8 6 2 9 2 6 Ü 3 8 2977±184
H R  (bpm ) 165±3 164±3 161±10 156±9 156±8 156±7 159±6 159±6 165±9 165±9
Table 2. Haemodynamic changes following LAD occlusion I (mean ± SEM, * p< 0.05 vs. baseline).
Control CBX #.04
Rotigaptide (pg/kg/min)
0.2 1
baseline occlusion baseline occlusion baseline occlusion baseline occlusion baseline occlusion
SA B P (H gm m ) 142±6 130±6* 147±7 133±9* 146±6 134±6* 145±7 136±8* 14U 11 129±12*
D A B P (H gm m ) 89±5 80±5* 101±5 91±7* 99±3 88±3* 97±6 89±6* 102±8 89±8*
M A B P (H gm m ) 107±5 97±5* 118±6 106±7* 115±4 103±7* 113±7 104±7* 115±9 103±9*
LV SP (H gm m ) 141±6 128±6* 142±7 133±8* 143±7 134±7* 143±7 135±7* 139±9 131±12*
L V E D P  (H gm m ) 7.1 ±0.4 13.8±0.6* 7±0.6 13.2±0.7* 6.8±0.3 11.8±0.4* 6.3±0.4 11±0.4* 6.6±0.4 12.8±1*
+ d P /d t (H gm m /s) 3107± 164 2518±142* 3 2 1 1±187 2715 ± 192* 3264±130 2807±86* 3063±152 2638±179* 3267±403 2860±431*
-d P /d t (H gm m /s) 2692±146 2133±121* 2700±164 2142±215* 2725±107 2455±133* 2924±178 2420±242* 2905±167 2404±172*
H R  (bpm ) 160±6 161±6 156±9 158±12 156±7 162±7 159±6 162±6 165±9 171±10
Table 3. Changes in dVldtml„ o f local electrogram (m Vis) and in ARI normalized ,o a cycle 
length o f 400 ms (ARUoo, in ms) as well as cycle length (ms) a, baseline (Omm) and after 10 
min administration o f rotigaptide (1 fig/kg/min, i.c.). Values are mean ± SEM.
dV/dt, 
0 min
min
10 min
ARIndO O
0 min 10 min
Cycle length 
0 min 10 min
Dog 1 -7.6±0.4 -7.5±0.3 169.3Ü.7 168.4±2.6 387 389
Dog 2 -7.7±0.7 -7.8±0.7 147.9Ü9 158.4±20.5 431
412
Dog 3 -9.4±1 -9.9±0.9 164.7±0.6 167±1.1 453 458
Dog 4 -5.6±0.7 -5.4±0.7 151.4±2 150.5±1 512 523
Dog 5 -7.7±0.9 -7.9±0.8 157± 1.3 158.6±1
557 561
3.1.4 Severity and distribution of ventricular arrhythmias induced by acute ischaemia in 
the presence of saline, carbenoxolone or rotigaptide
The distributions of VPBs over the 60 min LAD occlusion are illustrated in Figure 3. In the 
control dogs, arrhythmias occurred in two distinct phases termed as la and lb, thereafter, 
ectopic activity faded. Both arrhythmia phases were reduced by carbenoxolone as well as by 
rotigaptide. Interestingly, while CBX and the lowest dose of rotigaptide attenuated both 
phases of arrhythmias equally, higher doses of rotigaptide were particularly effective against
phase la arrhythmias.
Figure 4 depicts the total numbers of ventricular premature beats (VPBs) and tachycardlac 
episodes (VT) as well as the incidence of ventricular fibrillation (VF %) during the 60 min 
LAD occlusion. In the control group, there were a large number of VPBs and VT episodes, 
occurring predominantly in the first 25 min of the LAD occlusion, and 2 dogs out of 12 
fibrlllated during ischaemia. These were markedly reduced by both CBX and rotigaptide. 
Although there was no significant difference between the three rotigaptide dose groups, the 
number of VPBs slightly Increased when the two higher dose were applied, and the incidence 
of VF In the RG 1 group was not decreased but even higher than in the controls. VF 
incidence, however, showed no significant difference between any of the groups, probably 
because its low Incidence even in the controls.
Figure 3. Distribution ofVPBs during the 60 min LAD occlusion. *
Figure 4. Total numbers ofVPBs, VT episodes and the incidence ofVF during the first 25 
min (filled bars) and during 25-60 min o f ischaemia (open bars). Values are means ± SEM;
*p <0.05 vs. control.
3.1.5 Effects of carbenoxolone and rotigaptide on conduction abnormalities caused by 
ischaemia
The inhomogeneity of impulse conduction, shown on Figure 5A, was measured with the 
composite electrode in some control dogs and in the carbenoxolone group. The 
inhomogeneity of electrical activation increased steeply already in the first few minutes of 
ischaemia, which was followed by some decrease and a plateau phase during the rest of the 
occlusion period. Inhomogeneity was significantly reduced by CBX at any time point of the 
ischaemia.
In some control dogs and in the rotigaptide groups, impulse conduction was characterized 
using the total activation time (TATn4oo) assessed by activation mapping; this is illustrated by 
Figure 5B. Due to the better resolution of this technique, changes in TATn4oo in the control 
group follow the arrhythmia phases more sensitively: following a steep rise during phase la, 
there is a transient decrease but TATn4oo is elevated again during the lb phase and remains 
high during the second half of the occlusion. In the rotigaptide-treated dogs, although TATn40o 
values also increased during ischaemia, they were significantly lower than the control during 
both phase la and lb. The three doses of rotigaptide did not show any significant difference 
in their effects at any time point of the coronary occlusion.
Figure 5. Changes in the inhomogeneity o f electrical activation (A) and in TATn40o (B) during 
the 60 min LAD occlusion (mean ± SEM; *p< 0.05 vs. control).
3.1.6 Changes of myocardial electrical impedance during the 60 min LAD occlusion; 
effects of gap junction modifier agents
Figure 6 depicts relative changes in tissue resistivity and phase angle during the 60 min of 
ischaemia. In control animals, after an initial increase in resistivity and a decrease in phase 
angle, both parameters reached a plateau. A second, steep change in resistivity and phase 
angle occurred just prior to the lb phase of arrhythmias. Paradoxically, whereas ectopic 
activity faded after 30 min of ishaemia, both resistivity and phase angle showed further
changes.
Intracoronary infusion of CBX attenuated impedance changes and abolished the second steep 
rise in tissue resistivity as well as the drop in phase angle, indicating a reduced and more
gradual uncoupling.
Although impedance changes in the rotigaptide-treated dogs did not differ significantly from 
that observed in the controls, the biphasic manner of these changes was less apparent. In the 
RG 1 group, in parallel to the marked antiarrhythmic effect during phase la, early changes in 
resistivity and phase angle were significantly less than in the controls.
3.1.7 Effects of carbenoxolone and rotigaptide on ischaemia-induced gap junctional 
uncoupling determined by molecular analyses of the tissue samples
Gap junction permeability, assessed by double dye-loading of freshly excised tissue samples 
at the end of the LAD occlusion, was decreased by around 40 % in the ischaemic region of 
control hearts compared to the permeability measured in the non-ischaemic self-controls 
(Figure 7). This decrease was prevented by CBX as well as by all the three doses of 
rotigaptide: in these groups, gap junction permeability was almost identical in the ischaemic 
and in the non-ischaemic tissue samples.
Western blot analysis have shown a marked dephosphorylation of Cx43 in tissue samples 
originating from the ischaemic zone of control hearts (Figure 8), whereas the normal 
phosphorylation pattern was maintained by any dose of rotigaptide. Interestingly, despite to 
its protective effect against all the other parameters, CBX failed to prevent the 
dephosphorylation of Cx43.
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Figure 7. Gap junction permeability after 60 min o f ischaemia. Permeability o f 
the ischaemic tissue samples are expressed as percentage o f the non-ischaemic 
self-controls (mean±SEM; *p< 0.05 vs. non-ischaemic self-control).
Figure 8. The distribution o f phosphorylated (black bars) and dephosphorylated 
(grey bars) Cx43 expressed as a percentage o f total membrane Cx43 after 60 min o f 
ischaemia (mean ± SEM; *p< 0.05 vs. non-ischaemic).
3.2. Effects of ischaemic preconditioning on haemodynamic and 
electrophysiological alterations induced by acute ischaemia
3.2.1 Haemodynamic effects of LAD occlusion; effects of preconditioning and gap 
junction modification before ischaemia
These are shown in Table 4. Subsequent to LAD occlusion, arterial blood pressure and left 
ventricular systolic pressure, as well as positive and negative dP /dw  significantly decreased 
in all groups. LVEDP was significantly elevated, whereas the heart rate did not show 
significant difference neither between the groups nor after coronary artery occlusion.
3.2.2 The antiarrhythmic effect of ischaemic preconditioning
As shown on Figure 9, ischaemic preconditioning has markedly reduced both phases of 
arrhythmias during the 60 min LAD occlusion. The total number of VPBs, as well as the 
number of VT episodes and the incidence of VF (Figure 10) were also significantly reduced 
in the preconditioned dogs. It is also prominent on both figures that PC afforded an absolute 
protection against these arrhythmias instead of shifting them to a later period of the occlusion.
3.23 Amelioration of conduction slowing by preconditioning
Conduction properties in this group, similar to the controls, were studied by both the 
composite electrode (Figure 11A) and activation mapping (Figure I1B). Independently of the 
technique used, preconditioning significantly improved impulse conduction during the entire
occlusion period.
Table 4. Haemodynamic changes following LAD occlusion II  (mean ± SEM, * p< 0.05 vs. baseline).
Control PC CBX bef CBX+PC RG bef RG+PC
baseline occlusion baseline occlusion baseline occlusion baseline occlusion baseline occlusion baseline occlusion
SABP
(Hgmm)
142±6 130±6* 129±9 121±11* 141±5 131±4* 132±6 122±7* 144±10 132±10* 126±5 116±6*
DABP
(Hgmm)
89±5 80±5* 91±9 84±8* 89±4 80±5* 89±6 81 ±4* 92±7 82±9* 90±3 80±4*
MABP
(Hgmm)
107±5 97±5* 103±9 96±9* 106±4 97±5* 102±6 94±7* 106±8 95±9* 101±4 92±5*
LVSP
(Hgmm)
141±6 128±6* 129±9 122±10* 137±5 126±4* 131±7 122±8* 145±9 137±10* 126±6 118±5*
LVEDP
(Hgmm)
7.1 ±0.4 13.8±0.6* 7.2±0.3 12.5±1.1* 7±1 15±1* 8±1 16±1* 6.5±0.3 12.8±1.1* 6±0.4 11.9±0.7*
+dP/dt
(Hgmm/s)
3107±164 2518±142* 2843±198 2250±86* 2867±169 2446±148* 2923±149 2294±162* 3248±95 2602±31 * 2732±131 2395±127*
-dP/dt
(Hgmm/s)
2692±146 2133±121 * 2597±41 2070±76* 2562±170 2107±68* 2598±123 2141±134* 2728±237 2363±319* 2684±187 2204±162*
HR (bpm) 160±6 161±6 161±8 165±9 160±4 162±3
162±4 161±2 166±3 169±3 158±5 165±6
3.2.4. Reduction of gap junctional uncoupling by ischaemic preconditioning
As shown by Figure 12, changes in tissue impedance were substantially lower in the 
preconditined dogs throughout the ischaemic period and there was a lack of second steep 
changes both in resistivity and phase angle, indicating that preconditioning resulted in a 
Slower and more gradual uncoupling. It is also important to note that changes reflecting gap 
junctional uncoupling in the eontrol group were not only delayed by preconditioning, but 
indeed reduced.
Molecular analysis of tissue samples originating from preconditioned hearts have found the 
preservation of both gap junctional metabolic coupling and the phosphorylated state of Cx43 
(.Figures 13 and 14), thus confirmed that gap junctional communication was almost intact in
these hearts.
3.3 Effects of gap junction coupler/uncoupler drugs, applied instead of or 
together with preconditioning, on arrhythmias, conduction impairments and 
gap junctional uncoupling during LAD occlusion
3.3.1 Effects of gap junction modifier drugs applied either alone or together with 
preconditioning on arrhythmia severity during LAD occlusion
These are shown on Figures 9 and 10. The gap junction uncoupler carbenoxolone attenuated 
the antiarrhythmic effect of preconditioning as shown by the increased number of VPBs and 
VT episodes as well as a slight increase in VF incidence compared to the PC group. In 
contrast, CBX administration by itself resulted in an antiarrhythmic protection similar to
preconditioning.
Arrhythmia severity following the administration of rotigaptide by itself was similar to the 
controls, some values, such as the number of VT episodes and the incidence of VF, although 
not significantly, were even higher than in the control group. When RG was administered 
together with PC, it did not have any significant influence on the protective effect of PC.
Figure 9. Distribution o/VPBs during the 60 min LAD occlusion. *
Figure 10. Total numbers ofVPBs, VT episodes and the incidence ofVF during the first 25 
min (filled bars) and during 25-60 min o f ischaemia (open bars). Values are means ± SEM;
*p< 0.05 vs. control.
3.3.2 Changes in ischaemia-induced conduction impairments following 
carbenoxolone/rotigaptide infusion by itself or in combination with preconditioning
These were measured using the composite electrode in the carbenoxolone groups (Figure 
UA)and by activation mapping in experiments with rotigaptide ¡IB). CBX, when
applied alone, resulted in a similar, although somewhat less pronounced improvement in 
conduction slowing than PC, whereas, when applied together with preconditioning, the 
protective effect was abrogated by CBX.
When administered in preconditioned dogs, rotigaptide did not modify substantially the 
TATn400 reduction afforded by PC. Interestingly, infusion of rotigaptide by itself exerted a 
different effect on TATn40o than on arrhythmia severity since TATo40o was much smaller than 
the control values during both arrhythmia phases. It must be noted, however, that these lower 
TAT^oo values may originate from the loss of animals with more severe TATn400 changes due
to VF.
3.3.3 Effects of gap junction modifier drugs applied with and without preconditioning on 
gap junction function during the course of prolonged ischaemia
Compared to the controls, infusion of carbenoxolone by itself prior to the prolonged coronary 
occlusion has led to a reduced gap junctional uncoupling during the occlusion period, as it is 
shown by changes in tissue impedance (Figure 12) as well as by the preservation of gap 
junction permeability and Cx43 phosphorylation (Figures 13 and 14). In the CBX+PC group, 
attenuation of the antiarrhythmic effect of preconditioning was accompanied by a marked gap 
junctional uncoupling, as indicated by the rapid decrease in phase angle, the reduction in gap 
junction permeability and the dephosphorylation of Cx43.
The infusion of rotigaptide prior to ischaemia did not modify ischaemia-induced gap 
junctional uncoupling (although metabolic coupling was preserved in this group), nor the 
Protective effect of preconditioning as it was clearly represented by both in vivo and in vitro 
analyses of gap junction function.
35
Figure 13. Gap junction permeability after 60 min o f ischaemia. Permeability o f 
the ischaemic tissue samples are expressed as percentage o f the non-ischaemic 
self-controls (mean±SEM; *p< 0.05 vs. non-ischaemic self-control).
Figure 14. The distribution o f phosphorylated (black bars) and dephosphorylated 
(grey bars) Cx43 expressed as a percentage o f total membrane Cx43 after 60 min o f  
ischaemia (mean±SEM; *p< 0.05 vs. non-ischaemic).
4. DISCUSSION
4.1 New findings
(1) We have confirmed that gap junctional uncoupling and subsequent conduction slowing 
plays a role in the lb phase of acute ischaemia-induced arrhythmias in anaesthetised, open- 
chest dogs. We have also pointed out that during the later phases (after 30 min) of ischaemia, 
despite further gap junctional uncoupling, ectopic activity is diminished.
(2) We have found that both gap junction coupler and uncoupler drugs, applied prior to and 
continuously during ischaemia, are able to improve impulse conduction and attenuate
arrhythmias.
(3) Our study have demonstrated that ischaemic preconditioning markedly reduces ischaemia- 
induced gap junctional uncoupling, which, by the amelioration of impulse conduction, may 
contribute to the antiarrhythmic effect of preconditioning. It is of importance that in this 
model, preconditioning provides an absolute protection against gap junctional uncoupling, 
conduction slowing and arrhythmias, instead of shifting them to a later period of ischaemia.
(4) We have shown that the protective effect of ischaemic preconditioning can be attenuated if 
gap junctions are closed with carbenoxolone during the preconditioning stimulus. The 
protection induced by the administration of carbenoxolone by itself has suggested a possible 
role of gap junctional uncoupling also as a trigger for preconditioning. Although 
administration of the gap junction coupler rotigaptide during the preconditioning ischaemia 
does not influence the protective effects of preconditioning, some role of gap junctions or 
connexin proteins as triggers of preconditioning cannot be excluded.
4.2 Role o f gap junctional uncoupling in acute ischaemia-induced 
arrhythmogenesis
Continuous in vivo assessment of gap junctional coupling by the measurement of myocardial 
electrical impedance allowed us to compare gap junction function with changes in impulse 
conduction and arrhythmias over the entire experimental period. In control dogs, occlusion of 
the LAD was abruptly followed by an increase in tissue resistivity and a decrease in phase 
angle. It is tempting to speculate whether these changes reflect gap junctional uncoupling 
already at this early time point of ischaemia. However, determination of gap junction 
permeability and Cx43 phosphorylation in samples excised after 5 min of ischaemia (data not
shown) as well as earlier studies in a model that allowed the distinction between the extra- 
and intracellular components of tissue resistivity failed to demonstrate any significant 
uncoupling in this phase of ischaemia [29], These early changes in tissue impedance are 
rather signs of those rapid alterations in the ischaemic tissue such as the lack of blood due to 
the arrest of perfusion, changes in the extracellular space and cellular oedema [61, 62],
In contrast, gap junctional uncoupling is proved to be a contributing factor in the genesis of 
phase lb arrhythmias. Similar to earlier results obtained from in vivo or isolated porcine 
hearts [30, 44, 55], we have found a second steep rise in tissue resistivity and a decrease in 
phase angle just preceding the occurrence of phase lb arrhythmias. Molecular analyses of 
tissue samples taken after 25 min of ischaemia in some additional control dogs, by showing a 
significant decrease in gap junction permeability and dephosphorylation of Cx43 [60], 
provided further evidence for the presence of uncoupling in this phase. Closure of gap 
junctions during phase lb was also reflected by a second increase in TATn4oo, a more precise 
measure of conduction abnormalities than the inhomogeneity of activation determined by the
composite electrode.
Paradoxically, after 30 min of the LAD occlusion further changes in tissue impedance and 
still elevated TATn4oo values are no more accompanied by arrhythmias. The lack of 
arrhythmias despite advanced gap junctional uncoupling suggests that closure of gap 
junctions may provoke arrhythmias either only during a particular phase of ischaemia when 
uncoupling is too rapid or heterogeneous, or by acting synergistically with other 
arrhythmogenic factors. There is some evidence for this assumption established by Smith et 
al. [30]: in anaesthetised pigs, if gap junctional uncoupling has occurred much earlier than the 
lb phase, this early uncoupling was able to salvage these pigs from VF.
It may well be that rapid closure of gap junctions create heterogeneities in coupling and 
therefore also in impulse conduction throughout the affected tissue. This applies particularly 
to the border zone of the ischaemic area, which is the most heterogeneous region from both 
the metabolic and the electrophysiological aspect. Thus, it is conceivable that some groups of 
cells, already severely damaged by ischaemia, uncouple more rapidly than neighborous areas 
with more adequate perfusion, resulting in marked heterogeneities in impulse propagation and 
in an increased propensity for arrhythmias. Albeit focusing on questions other than the 
consequences of acute ischaemia, there is some evidence for the importance of heterogeneous 
coupling in arrhythmogenesis, as both patchy Cx43 expression in chimeric mice [35, 36] and 
redistribution of Cx43 in healing canine infarcts increase the propensity for ventricular 
arrhythmias [63, 65]. Computer simulation studies have also reported that at a given Na+
channel conductance, spatially heterogeneous uncoupling results in more reentry circuits than 
a more severe but homogenous uncoupling [65].
Others suppose that intermediate gap junctional uncoupling is responsible for phase lb 
arrhythmias since it has been shown both in vitro and in vivo that partial uncoupling may 
allow not only the spread of cell death but, once formed, the propagation of triggered activity 
as well [10, 44]. It can be explained by that intermediate uncoupling, by reducing electrotonic 
interaction but not affecting conduction, favours both the formation and spread of focal 
arrhythmias, however, substantial conduction slowing by advanced gap junctional uncoupling
inhibits their propagation.
On the other hand, gap junctional uncoupling is likely to influence arrhythmogenesis together 
with other factors. Accumulation of catecholamines in the ischaemic tissue, first, increases 
Ca2+ load of the myocytes and enhances triggered activity [7, 9, 10]; second, it may 
exaggerate the spatial heterogeneity of the effective refractory periods [11]; and third, it also 
contributes to the closure of gap junctions [66, 67]. Ventricular wall stretch, perhaps by 
further increasing Na+ and Ca2+ load, is also suggested to participate in arrhythmogenesis 
during the lb phase [68, 69]. Concerning the possible mechanism of phase lb arrhythmias, 
whereas catecholamines and wall stretch readily induce triggered activity, the slowing of 
impulse conduction secondary to gap junctional uncoupling form a substrate for reentry as 
well [23 31, 32, 33]. This can be further enhanced by the exaggeration of spatial 
heterogeneity of refractoriness by both catecholamines [11] and gap junctional uncoupling
[32, 70],
To conclude, it is well established that gap junctional uncoupling plays a role in acute 
ischaemia-induced arrhythmias, however, it is still unclear whether the extent or the timing of 
uncoupling is more important to determine arrhythmogenesis. Further investigations using 
more specific techniques and/or gap junction modifier agents may lead to a better 
understanding of this mechanism.
4.3 Attenuation of ischaemia-induced arrhythmias by gap junction modifier 
agents applied before and during ischaemia
The role of gap junctional uncoupling in acute ischaemia-induced ventricular arrhythmias was 
also confirmed by that maintenance of gap junctional coupling by the gap junction opener 
rotigaptide afforded protection against both ischaemia-induced conduction slowing and 
arrhythmias. Interestingly, higher doses of the peptide slightly increased the number of VPBs
and the highest dose did not protect against VF. A possible explanation for this phenomenon 
is, as discussed in details under point 4.2, that on one hand, maintenance of gap junctional 
coupling may reduce the risk of reentrant arrhythmias, however, on the other hand it may 
favour the formation and spread of triggered activity. Unfortunately, our activation mapping 
system does not allow clear distinction between these two arrhythmia mechanisms. In an 
attempt to distinguish clearly recognizable reentry and other types of arrhythmias, although 
we have found a reduction of the portion of reentry in the rotigaptide treated dogs (3 ± 1.6 % 
vs. 7.3 ± 2% in the controls), the low occurrence of clearly recognizable reentrant circuits 
even in the control group highlighted the limitations of this technique. Others, however, with 
the use of intramural 3D activation mapping provided evidence that after 3 hours of 
ischaemia, rotigaptide inhibited the induction of reentrant arrhythmias whereas focal 
arrhythmias could be readily provoked in the presence of the peptide [38, 71].
It was also prominent that the two higher doses of rotigaptide attenuated phase la arrhythmias 
more efficiently than the lowest dose. This is rather surprising as gap junctional uncoupling is 
reported to participate only in the formation of phase lb arrhythmias. Since non-gap-junction- 
specific cellular electrophysiological effects of rotigaptide have been excluded, this may be 
explained by that gap junctional uncoupling, which is insufficient to play a role during phase 
la but may start already within the first minutes of ischaemia, is inhibited by the peptide and 
this improved coupling counteracts with conduction slowing caused by Na+ channel 
inactivation. TATn4oo changes were also significantly smaller than the controls already during
phase la.
Maintenance of gap junctional coupling in all the three rotigaptide dose groups was verified 
by determination of gap junction permeability and phosphorylation of Cx43, but not by tissue 
impedance changes. This can be originated from the lower sensitivity of this technique i.e. 
impedance is influenced by other ischaemia-induced electrophysiological alterations as well, 
and these may mask changes in gap junctional coupling [61, 62].
In contrast to the antiarrhythmic effect of rotigaptide, the attenuation of arrhythmias by the 
gap junction uncoupler carbenoxolone was rather surprising. In this group, the marked 
reduction of arrhythmias was accompanied by more homogenous electrical activation 
probably resulting from a more gradual gap junctional uncoupling. These results further 
support the concept that gap junctional uncoupling is arrhythmogenic only during a particular 
period of ischaemia. Thus, it may well be that by the modification of the timing of gap 
junctional uncoupling with a gap junction blocker, an antiarrhythmic effect can be achieved. 
However, since this group shows great similarities to the group when carbenoxolone was
applied 20 min prior to ischaemia, it is also conceivable that carbenoxolone exerted some 
indirect, even non gap junction-specific effect already before the commencement of ischaemia 
and this led to the protective effect (for detailed discussion, see point 4.5). In order to clarify 
whether carbenoxolone was protective by direct modulation of gap junctional coupling, 
further experiments are needed with the use of other, relatively specific gap junction 
uncouplers such as palmitoleic acid or the peptide Gap27.
It is also worth to note that there are already some precedents in the literature for the 
protective effect of both gap junction opener and blocker agents in the same setting. It has 
been established that defibrillation energy required upon resuscitation can be decreased by 
both the gap junction coupler rotigaptide and the gap junction uncouplers stearic acid and 
heptanol [72, 73]. Infarct size due to ischaemia/reperfusion was also significantly decreased 
both by rotigaptide and heptanol, given either during the course of ischaemia or only during 
reperfusion [74, 39, 43, 75, 76]. Unfortunately, our model does not allow the study of infarct 
size, which in this case could not only serve as an additional endpoint, but could have the 
benefit to compare the effects of both a coupler and an uncoupler on infarct size in the same 
animal model and revise those earlier studies performed on different species under different 
experimental conditions.
In summary, the timing of gap junctional uncoupling appears to be more important in 
arrhythmogenesis than its extent. Furthermore, the antiarrhythmic protection found with the 
application of both a gap junction coupler and uncoupler agent, confirms that both are 
possible candidates in the development of new drugs against ischaemia/reperfusion induced 
arrhythmias and infarction.
4.4 The effect o f ischaemic preconditioning on ischaemia-induced gap 
junctional uncoupling and its relationship with the antiarrhythmic protection
In the preconditioned dogs, ischaemia-induced changes in tissue impedance were significantly 
lower than changes in the control dogs, this, together with the lack of the second steep rise of 
resistivity and decline in phase angle suggests a reduced and more gradual gap junctional 
uncoupling. Molecular analyses of tissue samples have also shown protection against 
ischaemia-induced gap junctional uncoupling. This protective effect probably contributed to 
the improved impulse conduction during the ischaemic period and to the marked reduction in 
arrhythmia severity.
It is important to note that in this model, i.e. in chloralose-urethane-anaesthetised, open-chest 
dogs, preconditioning offered an absolute protection against all the measured parameters 
instead of shifting them to a later phase of ischaemia. This differs from what others have 
observed and clearly shows the differences among the models used. In chloralose- 
anaesthetised pigs, a species with poor collateral circulation thus increased propensity for 
ischaemia-induced VF, both gap junctional uncoupling and ventricular arrhythmias were 
delayed by preconditioning with only a slight reduction in their severity [55]. However, a 
similar delay of gap junctional uncoupling and arrhythmias by preconditioning in 
pentobarbital-anaesthetised dogs emphasizes the importance of the anaesthetic used [56].
4.5 Gap junctions as potential triggers of ischaemic preconditioning
Gap junctions are also suggested to play a role in the trigger phase of preconditioning as well. 
As one may speculate, these direct cytoplasmic connections may promote the propagation of 
any endogenous mediators or second messengers of preconditioning, which are membrane- 
impermeable but smaller than 1 kDa, such as bradykinin, adenosine, some free radicals, cyclic 
nucleotides, IP3 and Ca2+. During the short preconditioning ischaemia, gap junctional 
uncoupling, if starts, does not hinder this interchange since metabolic coupling is still 
preserved even after 2 hours of ischaemia [77]. Indeed, intracoronary administration of the 
gap junction uncoupler carbenoxolone during the preconditioning stimulus could attenuate the 
beneficial effects of preconditioning since the severity of arrhythmias, the inhomogeneity of 
electrical activation and measures of gap junction function all indicated a reduced or no 
protection. This finding was in accordance with others reporting a similar diminution of 
protection if gap junctional communication was impaired during the induction of 
preconditioning [57, 58].
Interestingly, the application of carbenoxolone by itself as a drug control resulted in a 
protective effect. This protection was similar to preconditioning against arrhythmias, 
conduction abnormalities and gap junctional uncoupling. The fact that a gap junction 
uncoupler can mimic preconditioning has suggested that gap junctional uncoupling may serve 
as a trigger for preconditioning. According to this hypothesis, a slight gap junctional 
uncoupling induced by the preconditioning ischaemia, although it is not sufficient to create 
arrhythmias but may already start in this early phase, triggers preconditioning. However, if 
this uncoupling is stronger than the adequate stimulus (as it may happen in the CBX + PC
group), it is rather adverse than protective since the protection afforded by preconditioning is 
known to require an optimal duration and number of the preconditioning stimuli [78, 79],
In order to test this hypothesis, the gap junction opener rotigaptide was administered alone 
and together with preconditioning. Rotigaptide by itself did not trigger any protection, on the 
opposite, it seemed to slightly (although not significantly) increase both the severity of 
arrhythmias and mortality due to VF during ischaemia. Combination of the peptide with 
preconditioning, however, did not modify the protective effect of preconditioning from any of 
the aspects studied, thus failed to provide a further evidence for the trigger role of gap
junctional uncoupling.
As an alternative explanation, carbenoxolone could have induced a protective effect through a 
mechanism other than its uncoupler effect. Although carbenoxolone is proved to be 
ineffective on other sarcolemmal ion currents [23, 24], it is known to have corticoid-like 
effects and to induce the expression of the stress protein Hsp 70 and Cx43 as well [80, 81]. 
Nevertheless, the relatively short duration of these experiments and the local administration of 
the drug minimize the possibility of these non-specific actions.
On the other hand, connexin proteins may have other functions in myocytes as well. 
Hemichannels, if not integrated into gap junctions, may allow the movement of ions and 
molecules between the intra- and extracellular space and are reported to open during 
metabolic inhibition and contribute to cell death [82, 83]. They are also suggested to play a 
role in cellular osmoregulation [84], Furthermore, beside their pore-forming activity, there is 
a growing body of evidence for the signalling role of connexins. These proteins, due to the 
numerous phosphorylation sites on their C-terminals, can interact with many kinases and 
phosphatases [14, 15, 16] and due to their membrane localization, with cytoskeletal and cell 
adhesion proteins as well [15]. They also have been found in the nucleus [85, 86] and in the 
mitochondrial membrane [87]. These alternative functions of connexins have been suggested 
to play a role in preconditioning, since whereas preconditioning could not be induced in 
connexin43-deficient mice [88, 89], its protective effect was manifest in isolated myocytes 
with intact Cx43 expression but no gap junctional intercellular communication [90], Co­
localization of sarcolemmal Cx43 with PKCa and p38MAPKa and p during ischaemia and its 
enhancement by preconditioning [91], as well as translocation of sarcolemmal Cx43 to the 
mitochondrial membrane during preconditioning has also been reported [87, 92],
To summarize our results, gap junctions are likely to play a role already in the induction of 
preconditioning by allowing the cell-to-cell transfer of those endogenous substances released 
by the preconditioning stimulus. However, since modification of gap junctional coupling may 
influence the outcome of a subsequent ischaemic period, the trigger role of gap junctional 
uncoupling or other, non-gap-junction-related functions of connexin 43 also have to be
considered.
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